menu
    • menu
    [{"orgOrder":0,"company":"Delcath Systems","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2020","type":"Public Offering","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"Delcath Systems","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Delcath Systems \/ Roth Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Delcath Systems \/ Roth Capital Partners"},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Xi'an Guokang Ruijin Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Agreement","leadProduct":"Melphalan","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CASI Pharmaceuticals \/ Xi'an Guokang Ruijin Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"CASI Pharmaceuticals \/ Xi'an Guokang Ruijin Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals for Alkeran

    Menu

    Alkeran

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CASI Pharmaceuticals

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            CASI Pharmaceuticals

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melphalan

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Xi'an Guokang Ruijin Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Casi Pharmaceuticals Announces Renewal Of Exclusive Distribution Agreement For Evomela® In China

                            Details : Under the terms of the agreement, China Resources Pharmaceutical Commercial Group International Trading Co., will continue to be the sole distributor for the sale of EVOMELA® (melphalan) for Injection in China.

                            Product Name : Evomela

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            April 03, 2022

                            Lead Product(s) : Melphalan

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Xi'an Guokang Ruijin Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Delcath Systems

                            U.S.A arrow
                            Interphex
                            Not Confirmed

                            Delcath Systems

                            U.S.A arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melphalan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Roth Capital Partners

                            Deal Size : $22.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Delcath Systems Prices $22M Public Offering

                            Details : Delcath intends to use the net proceeds of the offering for working capital and general corporate purposes including the continued development of Melphalan/HDS.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            January 05, 2020

                            Lead Product(s) : Melphalan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Roth Capital Partners

                            Deal Size : $22.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth